





Bonfiglio, John N. - The Wall Street Transcript













































 





































John N. Bonfiglio
JOHN N. BONFIGLIO is Chief Executive Officer of The Immune Response
Corporation, a biopharmaceutical company co-founded by medical pioneer
Jonas Salk and based in Carlsbad, California. Prior to joining The
Immune Response Corporation, Dr. Bonfiglio was Chief Operating Officer
and Executive Vice President for Cypress Biosciences, a San Diego-based
biotechnology firm, from June 2001. While at Cypress Biosciences, he
oversaw the firm’s business, clinical, and research and development
efforts for its fibromyalgia drug. Prior to his tenure at Cypress
Biosciences, Dr. Bonfiglio spent four years at Peregrine
Pharmaceuticals, formerly known as Techniclone Corporation, a Tustin,
California-based biotechnology firm focused on cancer treatments. From
1999 to 2001, he served as President and Chief Executive Officer,
raising capital through a series of licensing agreements and equity
financing agreements and created and executed a strategic plan for
refocusing the company on clinical trials and licensing. Dr. Bonfiglio
was Vice President, Technology and Business Development of the company
from 1997 to 1999, and oversaw research and development, clinical and
regulatory affairs, interactions with the U.S. Food and Drug
Administration and all product-licensing activities. He also has served
as a Director for Baxter Healthcare Corporation, based in Irvine,
California, as Director of Business Development and Strategic Planning
in the Immunotherapy division and later in the Cardiovascular Surgical
division from 1994 to 1997. Dr. Bonfiglio began his biotechnology career
with positions at Allergan Inc. as a Scientist in 1983, becoming a
Project Director in 1987 and Director of Business Planning in 1991 and
eventually Director of Strategic Marketing for Allergan’s worldwide
ocular anti-infective franchise.
Related Interviews:JOHN BONFIGLIO - IMMUNE RESPONSE CORPORATION (IMNR)July 05, 2004John Bonfiglio - The Immune Response Corporation (imnr)July 28, 2003







CartLatest NewsJames Abate of Centre Asset Management Sees Consumer Demand Driving New Stock HighsMalcolm E. Polley of Stewart Capital and How to Play the Health Care StocksTimothy Biltz, CEO of Lumos Networks Identifies the Key Component for Future 5G NetworksThe Wall Street Transcript is a completely unique resource for investors and business researchers.Over 20,000 CEO, Equity Analyst and Money Manager InterviewsSubscribe now!Sign Up For Newsletter Weekly email with New In-Depth Interviews


Email: 



Most Popular InterviewsDelivering Long-Term Results with a Risk-Managed Growth FundJames A. Abate Published July 20, 2017 in Investing StrategiesCompanies covered: AMAT JNJ COH RL COG NVDA ADBE ATVI KLAC AMZN NFLX GOOG FB GLW MU 005930 000660 WFM JWN CMG GPS EQT RICE SPLS Buy ($25)Finding Investments with Favorable Risk and Reward OpportunitiesHenry  Beukema Published July 19, 2017 in Investing StrategiesCompanies covered: ORCL MSFT NSRGY AMZN WFM LRLCY AGN LNR Buy ($25)Better Returns and Lower Risk in the Midcap SpaceMalcolm E. Polley Published July 18, 2017 in Investing StrategiesCompanies covered: PRAA HURN FII FL NKE AMZN WFM WBA RAD Buy ($25)Most Popular ReportsWireless Communications & Telecom Published July 14, 2017Buy ($175)Investing Strategies Published July 11, 2017Buy ($175)Investing Strategies Published June 30, 2017Buy ($175) 






Top Company Interviews






Register for a Free Account to gain greater access to
            The Wall Street Transcript right now




CEO INTERVIEWSInterview with the President and CEO: Lumos Networks Corp. (NASDAQ:LMOS)Interview with the Corporate VP of Business Development, Strategy and Investor Relations: DSP Group, Inc. (NASDAQ:DSPG)Interview with the CEO and Director: Tactile Systems Technology, Inc. (NASDAQ:TCMD) 

SECTOR ROUNDTABLESNatural Gas Weighs Heavy On E&P Near-Term ProspectsRoundtable Forum:optimism Despite Uncertainty In For-profit EducationRoundtable Forum:a Shift In Focus To Natural Gas From Oil 

MONEY MANAGER INTERVIEWSDelivering Long-Term Results with a Risk-Managed Growth FundFinding Investments with Favorable Risk and Reward OpportunitiesBetter Returns and Lower Risk in the Midcap Space 

ANALYST INTERVIEWSAnalyzing the Secular Drivers Within Communications Infrastructure and TelecomSatellite Companies Benefiting from Growth in Data TrafficIncreased Focus on Content as Consumers Shift to Digital Consumption 




Subscribe Today!







                Since 1963
                © The Wall Street Transcript 1997-2016
Terms and Conditions
Privacy Policy  
            





https://www.twst.com/wp-admin/admin-ajax.php

Pin It on Pinterest





































Share This





Twitter





Facebook





Google+





Gmail





LinkedIn








































×





Join now for free!
Already a member?






First Name 





Last Name 





Email address *








Create new account
 


or create an account with a social network.

Join with Facebook


Join with Twitter


Join with Google








Username or Email address: *





Password: *






LoginJoin now! | Forgot password?
 


or login using a social network


Log in with Facebook


Log in with Twitter


Log in with Google





















Page not found - TheStreet

















 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street




































 
















Page not found

        Sorry, the page you're looking for is not available.
    
    You might want to try:
    

Our homepage


Our most popular stories






























 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 












 


John N Bonfiglio
 | LinkedIn
 


























 









LinkedIn



















































Main content starts below.




John N BonfiglioPresident and COO at TapImmune IncLocationTampa/St. Petersburg, Florida AreaIndustryBiotechnologyCurrentTapImmune Inc, Tapimmune, Bonfiglio Consulting GroupPreviousOragenics, Inc, Argos Therapeutics (ARGS), The Immune Response CorporationEducationPepperdine UniversityRecommendations1 person has recommended John N500+ connectionsView John N’S full profile. It's free!Your colleagues, classmates, and 500 million other professionals are on LinkedIn.View John N’S Full ProfileExperiencePresident and COOTapImmune IncJuly 2016  –  Present (1 year 1 month)Jacksonville, Florida AreaMember Board of DirectorsTapimmuneFebruary 2015  –  Present (2 years 6 months)Fund raising in public markets, drug development, investor relations, adviser to the CEOPrincipalBonfiglio Consulting GroupNovember 2014  –  Present (2 years 9 months)President and CEOOragenics, IncMay 2011  –  October 2014 (3 years 6 months)- Strategic refocusing of the Company- Two strategic collaborations with Intrexon Corporation- Raised $29M in new capital- Qualified Company for registration on NYSE: MKTS- Lowered base burn rate- Refocused R&D on  therapeutic areaPresident and CEOArgos Therapeutics (ARGS)January 2007  –  February 2010 (3 years 2 months)Raleigh-Durham, North Carolina AreaPresident and CEOThe Immune Response CorporationJanuary 2003  –  November 2005 (2 years 11 months)Chief Operating OfficerCypress BioScience2001  –  2002 (1 year)CEOPeregrine Pharmaceuticals1999  –  2001 (2 years)Vice President of Business DevelopmentPeregrine Pharmaceuticals1997  –  1999 (2 years)Director business developmentBaxter immunotherapy1994  –  1997 (3 years)Director strategic marketingAllergan1992  –  1994 (2 years)Director strategic marketingAllergan1983  –  1994 (11 years)scientistOCCIDENTAL CHEMICAL CORP1981  –  1982 (1 year)SkillsBiotechnologyLifesciencesPharmaceutical IndustryMedical DevicesOncologyCommercializationMergersTechnology TransferRegulatory AffairsImmunologyStart-upsFDALicensingClinical ResearchStrategic PlanningSee 19+Mergers & AcquisitionsMedical WritingR&DCROGLPDrug DevelopmentRegulatory SubmissionsBusiness DevelopmentBiopharmaceuticalsMarketingLeadershipClinical TrialsStrategyInfectious DiseasesDrug DiscoveryClinical DevelopmentVenture CapitalCross-functional Team LeadershipCorporate DevelopmentSee lessHow's this translation?Great•Has errorsThanks for your help!EducationPepperdine UniversityMBA, BusinessMBA, Business1990  –  1992University of California San DiegoPhD, ChemisrtyPhD, Chemisrty1976  –  1980SUNY Stony BrookBachelor of Science (BS), ChemistryBachelor of Science (BS), ChemistryRecommendationsA preview of what LinkedIn members have to say about John N:John is a CEO's CEO! He bleeds strategy and can hone in, with laser accuracy, where a company's needs  are. John is a natural leader who can bolster a strong steam as well as bring together disparate parties. John is also selfless...his ego does not get in the way of the mission. At any time he will roll up his sleeves and get into the thick of things. I'm lucky, as a business owner myself to have found another mentor. Leadership is synonymous with Dr. John Bonfiglio.See moreSee lessSign up to see who recommended John NGroupsResearch Triangle Life Sciences GroupView John N’S full profile to...See who you know in commonGet introducedContact John N directlyView John N’S Full ProfileView this profile in another languageEnglishGermanChinese (Simplified)People Also ViewedPatrick YeramianClinical research and drug developmentKathryn SimonSite Head Regulatory & Compliance at MerckPerry TateXXX at XXXCynthia Porter, MBAPresident of Porter Research "Go to Market" IT/HC Research  CompanyC Angel CooperDir of Business Operations to Chief Science Officer at Mallinckrodt PharmaceuticalsGary G. Altman, PhDBiotech and Life Sciences Business ExecutiveRichard SkowGeneral Counsel & Corporate Secretary Robin McCallumProject Director at TapImmuneMichael CardoneAna AlemanClinical Research AssociatePublic profile badgeInclude this LinkedIn profile on other websitesView profile badgesSearch by nameOver 500 million professionals are already on LinkedIn. Find who you know.First NameLast NameExample:  Jeff WeinerLinkedIn member directory:abcdefghijklmnopqrstuvwxyzmoreBrowse members by country



























TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer – TapImmune































































Skip to content




TapImmune
An immuno-oncology company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease.

AboutOverview Our Story Corporate Vision Company Management  TechnologyOverview Pipeline Clinical Pre-Clinical Patents  Collaborations InvestorsOverview Investor Briefcase Email Alerts Stock Info Financial Filings FAQ  News & EventsOverview Press Releases Events Media Coverage Press Kit / Media  Contact Us 







NSDQ: TPIV
$  ()
Download: Quick Fact Sheet

menu




AboutOverview Our Story Corporate Vision Company Management  TechnologyOverview Pipeline Clinical Pre-Clinical Patents  Collaborations InvestorsOverview Investor Briefcase Email Alerts Stock Info Financial Filings FAQ  News & EventsOverview Press Releases Events Media Coverage Press Kit / Media  Contact Us 






TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating OfficerYou are here:HomePress ReleasesTapImmune Appoints Dr. John N.…










JACKSONVILLE, Florida, July 19, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today that the Company has appointed Dr. John N. Bonfiglio, a member of its Board of Directors, as the Company’s President and Chief Operating Officer.
“Since joining TapImmune in early 2015 as a Strategic Advisor John has been a dynamic and thought-provoking colleague,” said Glynn Wilson, Chief Executive Officer. “His broad experience and expertise in biotech and immunotherapy has greatly strengthened our Company.”
“TapImmune’s strategy has never been more compelling,” said Dr. Bonfiglio, “Along with a team of drug development experts, I am excited to lead several Phase 2 trials and the potential to open a new Investigational Drug Application (IND) for our second T-cell vaccine product targeting Her2/neu in the next 6-8 months.”
About TapImmune Inc.
TapImmune Inc. is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at www.tapimmune.com for details.
Forward-Looking Statement Disclaimer:
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase II clinical trials, the ability to obtain regulatory approval of TPIV 200, the Company’s ability to raise future financing for continued development and the ability to successfully commercialize TPIV 200 as well as the risks and uncertainties set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
CONTACTS:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
(866)-359-7541





Share on Facebook
Share







Share on TwitterTweet







Share on Google Plus
Share






Share on LinkedIn
Share







Send email
Mail






Print
Print



Category: Press ReleasesJuly 19, 2016




CONTACT INFORMATIONPhone:
+1 (866) 359-7541

Email:
investor.relations@tapimmune.com

Address:
50 N. Laura Street, Suite 2500
Jacksonville, FL 32202Find us on:FacebookTwitter Company Updates(82)

In The Press(28)

Industry News(2)

Newsletter(14)

Our Blog(6)

Press Releases(81)

Science Publications(8)

 




Sign up for email alerts





Get our news delivered to your inbox


Sign Up Today








 












Join the TPIV VIP List


Don't miss out. Get our news delivered to your inbox.


 



 
 



















 















Join the TPIV VIP List
 



































Press Releases – TapImmune





























































Skip to content




TapImmune
An immuno-oncology company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease.

AboutOverview Our Story Corporate Vision Company Management  TechnologyOverview Pipeline Clinical Pre-Clinical Patents  Collaborations InvestorsOverview Investor Briefcase Email Alerts Stock Info Financial Filings FAQ  News & EventsOverview Press Releases Events Media Coverage Press Kit / Media  Contact Us 







NSDQ: TPIV
$  ()
Download: Quick Fact Sheet

menu




AboutOverview Our Story Corporate Vision Company Management  TechnologyOverview Pipeline Clinical Pre-Clinical Patents  Collaborations InvestorsOverview Investor Briefcase Email Alerts Stock Info Financial Filings FAQ  News & EventsOverview Press Releases Events Media Coverage Press Kit / Media  Contact Us 






Category Archives: Press ReleasesYou are here:HomeCategory "Press Releases"

















TapImmune CEO Glynn Wilson to Chair Panel Discussion on the Future of Combination Therapies in Oncology
Featured, Newsletter, Press ReleasesBy Aaron SantosJuly 18, 2017Hear from Randal H. Henderson, MD,Professor,Department of Radiation Oncology and Associate Medical Director at the UF Health Proton Therapy Institute, and enjoy a panel discussion led by Glynn Wilson, PhD, Chairman & CEO of TapImmune, Inc.









TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer
Featured, Newsletter, Press ReleasesBy Aaron SantosJune 27, 2017TapImmune has enrolled 50% (40/80) of the patients in its randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV 200 for treating triple-negative breast cancer (TNBC).









TapImmune Inc. Enters into Definitive Agreements to Raise $6.82 Million in a Private Placement from Accredited Investors and from the Exercise of Warrants by Existing Institutional Investors
Featured, Newsletter, Press ReleasesBy Aaron SantosJune 22, 2017TapImmune has entered into definitive subscription agreements to raise aggregate gross proceeds of approximately $6.82 million in a private placement transaction with accredited investors and from the exercise of certain outstanding Series E warrants by certain existing institutional investors.









TapImmune to Present at 2017 Biotechnology Innovation Organization International Convention
Featured, Press ReleasesBy Aaron SantosJune 14, 2017Dr. Glynn Wilson, Chairman and CEO of TapImmune, will present at the 2017 Biotechnology Innovation Organization International Convention held on June 19-22 in San Diego.









TapImmune Provides First Quarter 2017 Corporate and Clinical Update Today
Featured, Press ReleasesBy Aaron SantosMay 31, 2017TapImmune is hosting a conference call and live audio webcast today, May 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the first quarter 2017.









TapImmune to Provide First Quarter 2017 Business Update  Conference Call and Webcast
Featured, Newsletter, Press ReleasesBy webmasterMay 18, 2017TapImmune, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, May 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the first quarter 2017.









Richard Kenney, MD, FACP, Joins TapImmune to Lead the Clinical Development Program
Featured, Newsletter, Press ReleasesBy Aaron SantosMay 1, 2017TapImmune announced that on May 1, 2017, Dr. Richard Kenney will manage TapImmune’s ongoing and planned clinical programs for its next-generation T-cell vaccine candidates, which currently include multiple Phase 2 trials in advanced breast and ovarian cancer.






TapImmune Announces Change in Management and Board of Directors
Featured, Press ReleasesBy Aaron SantosApril 28, 2017TapImmune Inc. announced that on April 28,2017, Dr. John Bonfiglio resigned as Chief Operating Officer, President and director of TapImmune Inc. to pursue other opportunities. 









TapImmune to Participate in Two Upcoming Investor and Industry Conferences
Featured, Press ReleasesBy Aaron SantosMarch 22, 2017Dr. Glynn Wilson, Chairman and CEO of TapImmune, will provide an overview of the company’s business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform during his presentation at the 5th Annual Cancer Biopartnering & Investment Forum






TapImmune Provides Year End 2016 Corporate and Clinical Update
Featured, Press ReleasesBy webmasterMarch 14, 2017TapImmune today provided its first quarterly business update, following the company’s uplisting to The NASDAQ Capital Market in the fourth quarter 2016.  A public conference call and live audio webcast is scheduled for today at 4:30 pm ET.


12345…6789




Sign up for email alerts





Get our news delivered to your inbox


Sign Up Today






 












Join the TPIV VIP List


Don't miss out. Get our news delivered to your inbox.


 



 
 



















 















Join the TPIV VIP List
 
































TPIV John N. Bonfiglio Insider Trades for TapImmune Inc.


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































TapImmune Inc.

                  NASDAQ: TPIV
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

TapImmune Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 21, 2017, 3:59 p.m.


TPIV

/quotes/zigman/79954520/composite


$
3.60




Change

+0.12
+3.45%

Volume
Volume 25,194
Quotes are delayed by 20 min








/quotes/zigman/79954520/composite
Previous close

$
			3.48
		


$
				3.60
			
Change

+0.12
+3.45%





Day low
Day high
$3.41
$3.67










52 week low
52 week high

            $3.08
        

            $7.15
        


















Insider Activity


Individual




John N. Bonfiglio



Dr. John N. Bonfiglio is on the Board of Directors at TapImmune, Inc. and Microlin Bio, Inc. Dr. Bonfiglio was previously employed as President, Chief Executive Officer & Director by Oragenics, Inc., President & Chief Executive Officer by Intrexon Corp., President, Chief Executive Officer & Director by Transdel Pharmaceuticals, Inc., President & Chief Executive Officer by Argos Therapeutics, Inc., President & Chief Executive Officer by Immune Response Corp., Chief Operating Officer & Executive Vice President by Cypress Bioscience, Inc., President & Chief Executive Officer by Peregrine Pharmaceuticals, Inc., Director-Business Planning by Allergan, Inc., Director-Strategic Business Unit by Baxter Healthcare Corp., and President & Chief Executive Officer by Immune Response Corp. He also served on the board at Microlin Bio, Inc. /Old/. He received his undergraduate degree from Stony Brook University, a graduate degree from the University of California San Diego, an MBA from Pepperdine University and a doctorate degree from the University of California San Diego.



Transactions


Date
Shares
Transaction
Value





03/09/2017
5,220


 
Award at $0 per share.


0


12/12/2016
10,417


 
Gift at $0 per share.


0


12/12/2016
10,417


 
Gift at $0 per share.


0


12/12/2016
10,417


 
Derivative/Non-derivative trans. at $1.74 per share.


18,125


07/15/2016
250,000


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Glynn  Wilson 
Chairman, President & Chief Executive Officer




Mr. Michael J. Loiacono 
Chief Financial Officer, Secretary & Treasurer




Ms. Elizabeth  Donnelly 
Director-Administration




Mr. Frederick Gerald Wasserman 
Independent Director




Mr. Mark  Reddish 
Independent Director




Mr. Joshua N. Silverman 
Independent Director




Ms. Sherry  Grisewood 
Independent Director




Dr. David  Laskow-Pooley 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




10:51 AM EDT
July 22, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
10:39aWhy one analyst calls this the ‘chart of the week, month and potentially year’
10:07aThe cracked benchmark? Why some investors want a new standard for bonds
10:05a7 money-making lessons from the richest man who ever lived
10:03aGE’s stock falls as Jeff Immelt’s 64th and last quarter is another disappointment
10:01aNolan’s cinematic vision in ‘Dunkirk’ is Hollywood’s best defense against Netflix
9:59aAlphabet earnings: A $2.74 billion hit for Google, potential YouTube results for investors
9:58aMicrosoft rides huge tax benefit from failing at smartphones to big earnings beat 
9:53aTrump says he has ‘complete power to pardon’
9:29aChipotle earnings: Media coverage of the latest illness scare will put earnings targets at risk
9:24aExxon earnings: Will stock trade higher on expected second-quarter beat?
9:20aPay TV expected to lose more than a million subscribers in latest quarter 
9:20aQualcomm’s issues go beyond Apple fight
9:20aYogaWorks IPO pulled on valuation concerns, not market conditions
9:18aAmazon’s foray into groceries means more mergers of food companies, experts say
9:00aThis is what should really worry you about stocks
8:26aEuro rally has room to run if this pattern continues to hold true
8:25aWeekend roundup: Companies that may cut dividends | FAANG stocks and market bubbles | Enjoy London on the cheap
8:25aAttention, shoppers: ‘Amazon effect’ is creating bargain stocks
8:25aWhy you might want to avoid these 30 dividend stocks
8:21aStocks brace for volatility in earnings deluge; Fed meeting looms 
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15
























































	Transdel Pharmaceuticals Inc Appoints John N Bonfiglio Ph D as Chief Executive Officer and President













































Employer:
Login
Post Jobs


Job Seeker:
Login
Sign Up

























Search Life Sciences Jobs





Search Job Title Only












Radius:
Miles



Km80.5
















                 News | News By Subject | News by Disease |  
    News By Date | Search News



















Get Our FREEIndustry eNewsletter

email:


*
            
*
            



















 

 






Transdel Pharmaceuticals, Inc. (TDLP.OB) Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President  











Tweet








10/21/2010 7:37:05 AM


>LA JOLLA, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced the appointment of John N. Bonfiglio, Ph.D. as Chief Executive Officer and President.  Dr. Bonfiglio will also serve as a director on Transdel's Board of Directors.With over 27 years of pharmaceutical industry experience, Dr. Bonfiglio brings to Transdel his background in working with pharmaceutical companies during the development stage as well as those with commercialized products.  Given his experience, the Board of Directors is extremely pleased to have Dr. Bonfiglio join Transdel to continue to drive the vision of the Company.  "I believe that Transdel has the opportunity to become a successful pharmaceutical company," stated Dr. Bonfiglio.  "Our lead product, Ketotransdel®, has an opportunity to be the first topical ketoprofen product approved in the U.S. and also to become a 'best in class' product in the growing topical NSAID market. I am looking forward to leading this talented team in growing the Company's pharmaceutical and cosmeceutical businesses.  Increasing shareholder value is number one on my agenda."  Most recently, Dr. Bonfiglio worked as the President and Chief Executive Officer of Argos Therapeutics in Durham, NC and prior to that he was the Chief Executive Officer of The Immune Response Corporation in Carlsbad, CA.  He was also the Chief Executive Officer of Peregrine Pharmaceuticals and held senior management positions with Cypress Biosciences, Baxter Healthcare and Allergan, Inc.  About Transdel Pharmaceuticals, Inc.Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier.  Ketotransdel®, the Company's lead pain product candidate, has completed a Phase 3 clinical trial and utilizes the Transdel technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company intends to leverage its Transdel platform technology to expand and create a portfolio of topical products for a variety of indications.  The Company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products.  For more information, please visit http://www.transdelpharma.com.Safe Harbor StatementThe Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the Company's interpretation of the results of its Phase 3 clinical trial for Ketotransdel®; the Company's ability to obtain regulatory approval to market Ketotransdel; and the Company's ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the FDA may not agree with the Company's interpretation of the results of the Phase 3 clinical trial for Ketotransdel or may challenge the adequacy of the Company's clinical trial design or the execution of the clinical trial; the FDA may require the Company to complete additional clinical trials for Ketotransdel® before the Company can submit a 505(b)(2) NDA application; the results of any future clinical trials may not be favorable and the Company may never receive regulatory approval for Ketotransdel®; and the Company's current need to raise additional funding to complete its product development and clinical trial plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. SOURCE  Transdel Pharmaceuticals, Inc.






                Read at
                BioSpace.com







Related News
Transdel Pharmaceuticals, Inc. (TDLP.OB) Reports Second Quarter and Year-to-Date 2010 Results  BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors  Data from Transdel Pharmaceuticals, Inc. (TDLP.OB)'s Phase 3 Study to be Presented at 13th World Congress on Pain  PharmAthene, Inc. Appoints Eric I. Richman President and Chief Executive Officer  Transdel Pharmaceuticals, Inc. (TDLP.OB) to Present at Rodman & Renshaw 12th Annual Healthcare Conference  PPD, Inc. (PPDI) Appoints Former Roche (RHHBY) Exec, Andreas Tschirky as Leader of BioDuro, LLC
Transdel Pharmaceuticals, Inc. (TDLP.OB) Presents Phase 3 Study Data on Ketotransdel(R) at World Pain Congress in Montreal, Canada  Stem Cell Assurance Announces Appointment of Mark Weinreb, M.S. as Chief Executive Officer and Board Member  Transdel Pharmaceuticals, Inc. (TDLP.OB) to Present at 2010 Southern California Investor Conference  Agile Therapeutics, Inc. Appoints New President and CEO Al Altomari as Company Prepares for Commercialization Phase  




Please enable JavaScript to view the comments powered by Disqus.
comments powered by Disqus






















                            •
                            BioSpace.com










                            •
                            Transdel Pharmaceuticals, Inc.




             
        





                            •
                            Biotech/Pharma - Personnel




             
        















                              
                            

                              
                             
                              
                            

                              
                            








                 


















































 



 TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer 
         










    









 






 











 









TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer

Jul 19, 2016, 08:30 ET
		  		  						
						 from   TapImmune Inc. 











 
















































 

 




















 


JACKSONVILLE, Florida, July 19, 2016 /PRNewswire/ --
TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today that the Company has appointed Dr. John N. Bonfiglio, a member of its Board of Directors, as the Company's President and Chief Operating Officer.
"Since joining TapImmune in early 2015 as a Strategic Advisor John has been a dynamic and thought-provoking colleague," said Glynn Wilson, Chief Executive Officer. "His broad experience and expertise in biotech and immunotherapy has greatly strengthened our Company."
"TapImmune's strategy has never been more compelling," said Dr. Bonfiglio, "Along with a team of drug development experts, I am excited to lead several Phase 2 trials and the potential to open a new Investigational Drug Application (IND) for our second T-cell vaccine product targeting Her2/neu in the next 6-8 months."
About TapImmune Inc.
TapImmune Inc. is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at http://www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase II clinical trials, the ability to obtain regulatory approval of TPIV 200, the Company's ability to raise future financing for continued development and the ability to successfully commercialize TPIV 200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
CONTACTS:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1-866-359-7541


 SOURCE  TapImmune Inc.  




  

 View Table Fullscreen 




  View Table Fullscreen 





Journalists and Bloggers
The news you need, when you need it.
 
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.
LEARN MORE




 

 
 



















































  











Aug 11, 2016, 09:00 ET
Preview: TapImmune Enters into Definitive Agreements to Raise $8.5 Million From the Exercise of Outstanding Warrants and in a Private Placement from New Investors













Jun 21, 2016, 08:30 ET
Preview: TapImmune Doses First Patient in Its Phase 2 Triple Negative Breast Cancer Trial for Cancer Vaccine TPIV 200






My News


  Release contains wide tables.	  View fullscreen.






 Read More











Jun 22, 2017, 09:18 ET
TapImmune CEO Glynn Wilson to Chair Panel Discussion on the...














Jun 22, 2017, 09:18 ET
TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2...














Jun 22, 2017, 09:18 ET
TapImmune Inc. Enters into Definitive Agreements to Raise $6.82...











Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

 















Search











Searching for your content...









Advanced Search












































 


 Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and... ( LA JOLLA Calif. Oct. 21 /- Transdel P...)HomeBiologyMedicineTechnologyProductsNewsDefinitionDictionaryMoviesLinksSearchRSSNavigation LinksBiology NewsMedicine NewsBiology ProductsMedicine ProductsBiology DefinitionMedicine DefinitionBiology TechnologyMedicine TechnologyBiology DictionaryMedicine DictionaryHOME >> MEDICINE >> TECHNOLOGYTransdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President...LA JOLLA Calif. Oct. 21 /- Transdel Pharmaceu...With over 27 years of pharmaceutical industry experience Dr. Bonfigli... I believe that Transdel has the opportunity to become a successful ph...Most recently Dr. Bonfiglio worked as the President and Chief Executi... http://www.bio-medicine.org/inc/biomed/medicine-technology.asp http://feeds.bio-medicine.org/latest-medical-technologyDate:10/21/2010   

LA JOLLA, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board:  TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced the appointment of John N. Bonfiglio, Ph.D. as Chief Executive Officer and President.  Dr. Bonfiglio will also serve as a director on Transdel's Board of Directors. With over 27 years of pharmaceutical industry experience, Dr. Bonfiglio brings to Transdel his background in working with pharmaceutical companies during the development stage as well as those with commercialized products.  Given his experience, the Board of Directors is extremely pleased to have Dr. Bonfiglio join Transdel to continue to drive the vision of the Company.   "I believe that Transdel has the opportunity to become a successful pharmaceutical company," stated Dr. Bonfiglio.  "Our lead product, Ketotransdel®, has an opportunity to be the first topical ketoprofen product approved in the U.S. and also to become a 'best in class' product in the growing topical NSAID market. I am looking forward to leading this talented team in growing the Company's pharmaceutical and cosmeceutical businesses.  Increasing shareholder value is number one on my agenda."   Most recently, Dr. Bonfiglio worked as the President and Chief Executive Officer of Argos Therapeutics in Durham, NC and prior to that he was the Chief Executive Officer of The Immune Response Corporation in Carlsbad, CA.  He was also the Chief Executive Officer of Peregrine Pharmaceuticals and held senior management positions with Cypress Biosciences, Baxter Healthcare and Allergan, Inc.   About Transdel Pharmaceuticals, Inc. Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel™ cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier.  Ketotransdel®, the Company's lead pain product candidate, has completed a Phase 3 clinical trial and utilizes the Transdel™ technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company intends to leverage its Transdel™ platform technology to expand and create a portfolio of topical products for a variety of indications.  The Company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products.  For more information, please visit http://www.transdelpharma.com. Safe Harbor Statement The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the Company's interpretation of the results of its Phase 3 clinical trial for Ketotransdel®; the Company's ability to obtain regulatory approval to market Ketotransdel; and the Company's ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the FDA may not agree with the Company's interpretation of the results of the Phase 3 clinical trial for Ketotransdel or may challenge the adequacy of the Company's clinical trial design or the execution of the clinical trial; the FDA may require the Company to complete additional clinical trials for Ketotransdel® before the Company can submit a 505(b)(2) NDA application; the results of any future clinical trials may not be favorable and the Company may never receive regulatory approval for Ketotransdel®; and the Company's current need to raise additional funding to complete its product development and clinical trial plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.   '/>"/>SOURCE    Transdel Pharmaceuticals, Inc.Copyright©2010 PR Newswire.All rights reserved0GOODRelated medicine technology :1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program2. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain3. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial4. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference5. Transdel Pharmaceuticals Announces Management Reorganization6. Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO

Post Your Comments: *Name:*Comment: *Email: (Date:7/17/2017)... July 17, 2017  MedX Holdings, Inc., the manufacturer ... strengthening and rehabilitation equipment, today announced the national roll ... is considered the gold standard for the treatment of ... medical strengthening equipment.       ... the physician or practice who prescribe the MedX Home ... (Date:7/13/2017)... 2017  Centurion Medical Products, a leader in medical product innovation ... impaction removal device for hospice patient care.     ...       Centurion Medical Products   ...   Patient pain management and emotional comfort are part of ... patient pain while preventing unneeded emergency department admission due to severe ... (Date:7/12/2017)... -- Eli Lilly and Company (NYSE:   LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ®  (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ... Breaking Medicine Technology:[0] MedX Announces National Roll Out of Home Back Machine Program[1] Centurion's DisImpactor for Hospice Fecal Impaction Solution Reduces Pain and Possible Admission to Emergency Department[0] Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation(Date:7/21/2017)...               ...    July 21, 2017 ,        ...          West Dermatology is pleased to ... PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network of ... in dermatology,  skin cancer , and more. She graduated from the University of ... (Date:7/21/2017)...              ...     July 21, 2017 ,      ...             How ... are on the rise, say researchers presenting their work at the  American ... , “The combination of evaluating the patterns of change in concussion symptom presentation, ... (Date:7/20/2017)...              ...   July 20, 2017 ,        ...           Acute myeloid leukemia ... that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and ... and relapse.  With such a challenging diagnosis that requires immediate action, patients ... (Date:7/20/2017)...               ...    July 20, 2017 ,        ...          For individuals with extended hospital ... adjustable beds used in such facilities are specially designed to accommodate patients with a ...  , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, ... (Date:7/20/2017)...               ... 20, 2017 ,            ...      Doctors on Liens, the leading network of medical providers ... directed by Dr. Russell Horine, DC to their exclusive list of medical professionals. Horine ... Horine serving as the clinic director and his son Dr. Lee Horine and daughter-in-law ... Breaking Medicine News(10 mins):[0] West Dermatology Fresno Happy to Announce July Arrival of “Tu” Tuantu Doan Vu, PA-C[0] Assessing Concussion Symptom Presentation May Provide Insight into Rise in Rates[0] The Leukemia & Lymphoma Society and PlatformQ Health Present Virtual Education Event for Cancer Patients with Acute Myeloid Leukemia (AML)[0] Adjustable and Portable Arm Support Device Invented by InventHelp Client (IPL-405)[0] Doctors on Liens Announces Partnership with Distinguished Chiropractors in the Central ValleyBiology NavigationAIDS/HIVBioinformaticsBiotechnologyBiochemistryCancerCell BiologyDevelopmental BiologyEcologyEnvironmentEvolutionFood TechnologyGeneGeneticsGenomicsHealth/MedicineImmunologyMicroarrayMicrobiologyMolecularMarine BiologyNanobiotechnologyNeurobiologyPlant SciencesStem CellSystems BiologyVirusWomen HealthMedical NavigationAbortionAchesADHDAddictionAlcoholAllergyAlternative MedicineAlzheimer's DementiaAnxiety/StressArthritisAutismBacteriaBloodBird Flu/Avian FluBonesBreast CancerCancerCardiovascularCervical CancerChikungunyaCholesterolClinical TrialsColorectal CancerConferencesCrohn'sCystic FibrosisDengueDentistryDepressionDiabetesDrugEating DisordersEducationEpilepsyErectile DysfunctionEye Health/BlindnessFertilityFlu/ColdGastroIntestinalGeneticsGoutHeadache/MigraineHearing/DeafnessHIV/AIDSHuntington's DiseaseHypertensionImmune System/VaccinesInsuranceInfectious DiseasesIrritable-Bowel SyndromeInternetLeukemiaLifestyleLiver Disease/HepatitisLung CancerLupusMad Cow DiseaseMedical DevicesMedical Students/TrainingMedicare/MedicaidMedicoMen's healthMental HealthMRI/UltrasoundMRSA/Drug ResistanceMultiple SclerosisMuscular DystrophyNeurologyNursingNutrition/DietObesity/Weight LossPain/AnestheticsParkinson's DiseasePediatrics/Children's HealthPharma/Biotech IndustryPharmacy/PharmacistsPregnancyPrematureProstatePsychology/PsychiatryRehabilitationRespiratory/AsthmaSARSSchizophreniaSeniors/AgingSexual HealthSleep/Sleep DisordersSmokingStatinsStem Cell ResearchStrokeSurgeryTransplants/Organ DonationsVirusesWater - Air QualityWomen's HealthCopyright © 2003-2012 Bio-Medicine.  All rights reserved.ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS

























 



 TapImmune Appoints John N. Bonfiglio, Ph.D., to its Board of Directors 
         










    










 






 











 









TapImmune Appoints John N. Bonfiglio, Ph.D., to its Board of Directors

		  Accomplished Biotech CEO is currently a Strategic Advisor to TapImmune
		

Jul 30, 2015, 08:30 ET
		  		  						
						 from   TapImmune Inc. 











 
















































 

 




















 


SEATTLE, July 30, 2015 /PRNewswire/ -- TapImmune Inc. (OTCMKTS: TPIV) is pleased to announce the appointment of John N. Bonfiglio, Ph.D., MBA to its Board of Directors.  Since February, 2015 Dr. Bonfiglio has been a Strategic Advisor to the management team assisting with financing, development, and implementation of an improved Capital Markets and Shareholder IR/PR program.
Dr. Bonfiglio is a highly successful Biotech CEO with broad experience in corporate strategy, financing, market interactions, and business development.  Most recently, Dr. Bonfiglio served as President and CEO of Oragenics, where he refocused the company and raised over $29 million dollars in the public markets while positioning the company for a successful re-listing on the New York Stock Exchange (NYSE). Prior to joining Oragenics, he served as President and CEO of Argos Therapeutics, where he raised over $35 million dollars for the Company and led the company in a successful Phase 2 study in renal cell carcinoma.  As President and CEO of the Immune Response Corporation, he was responsible for turning the Company around through improved therapeutic focus, capital raising (over $50 million), and improved investor relations resulting in a significant appreciation in stock price and shareholder value.   Dr. Bonfiglio also served as President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation's Immunotherapy Division.
John received his Ph.D from the University of California, San Diego, and an MBA from Pepperdine University.
Dr. Glynn Wilson, Chairman & CEO of TapImmune, stated, "We welcome John to the TapImmune Board of Directors.  For the past six months, John has been working as a strategic advisor to the management team. His input has had a measureable impact on the advances we have made in the areas of investor and shareholder communications, as well as technical and clinical development. As our newest Board member, we look forward to drawing more deeply on his broad experience and success as a biotech executive.  His deep industry background will to enhance the overall capabilities of the Board as we enter Phase II clinical trials and the next phase of our growth."
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious disease. The Company's, peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details. 
Forward-Looking Statement Disclaimer 
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements. 
CONTACTS:
TapImmune Inc., Glynn Wilson, Ph.D.Chairman & CEO(866)-359-7541
PCG AdvisoryKirin M. SmithChief Operations Officer+1-(646)-863-6519
Sean LeousChief Communications Officer+1-(646) 863-8998www.pcgadvisory.com
 SOURCE  TapImmune Inc.  

RELATED LINKS
http://www.tapimmune.com



  

 View Table Fullscreen 




  View Table Fullscreen 





Journalists and Bloggers
The news you need, when you need it.
 
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.
LEARN MORE




 

 
 



















































  











Sep 02, 2015, 08:00 ET
Preview: TapImmune Inc. to Present at 17th Annual Rodman & Renshaw Healthcare Conference













Jun 23, 2015, 08:30 ET
Preview: TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients






My News


  Release contains wide tables.	  View fullscreen.






 Read More











Jun 22, 2017, 09:18 ET
TapImmune CEO Glynn Wilson to Chair Panel Discussion on the...














Jun 22, 2017, 09:18 ET
TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2...














Jun 22, 2017, 09:18 ET
TapImmune Inc. Enters into Definitive Agreements to Raise $6.82...











Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

 















Search











Searching for your content...









Advanced Search












































 


 


Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft















Background Checks and Public Records Search - Truthfinder








 


















Call Toll Free!  (800) 699-8081



Public Records Search
Social Media, Photos, Police Records, Background Checks, Contact Information and Much More!









START HERE - Try searching a friend, relative, celebrity, yourself, or someone else you might know...



First Name:





Last Name:





City:





State:


All States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
District Of Columbia
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming





This is me
Searching for yourself?




Search






  This secure connection is confirmed




We're Very Popular















What Our Happy Users Are Saying




"TruthFinder.com is freakishly accurate… Really scary how much info is out there." -Zac K.


"You found an old friend for me. Thank you." -Nancy V.


"TruthFinder is an excellent site for finding out about someone." -Sherrie F.


"This site is so wonderful. I found my lost godchildren and their mom. Thank you so much." -Lawrence W.


"This is one way to really know a potential date." -Charmaine R.


"Your service is more than perfect. It is a blessing. Thank you for the very hard work that you do." -Richard B.


"Truthfinder is a very accurate updated system. Their information is proper. And can be very helpful too." -Juan M.









Notice
This site contains REAL police records (court records of driving citations, speeding tickets, felonies, misdemeanors, sexual offenses, mugshots, etc.), background reports, photos, court documents, address information, phone numbers, and much more. Please BE CAREFUL when conducting a search and ensure all the information you enter is accurate.
Learning the truth about the history of your family and friends can be shocking, so please be cautious when using this tool.
TruthFinder does not provide consumer reports and is not a consumer reporting agency. We provide a lot of sensitive information that can be used to satisfy your curiosity, protect your family, and find the truth about the people in your life. You may not use our service or the information it provides to make decisions about consumer credit, employers, insurance, tenant screening, or any other purposes that would require FCRA compliance.
I Understand


Help Us Refine Your Results

Select Your Gender



Male



Female

NEXT

Skip


What's Your Age?


Submit
I don't know

Skip























Background Checks and Public Records Search - Truthfinder








 


















Call Toll Free!  (800) 699-8081



Public Records Search
Social Media, Photos, Police Records, Background Checks, Contact Information and Much More!









START HERE - Try searching a friend, relative, celebrity, yourself, or someone else you might know...



First Name:





Last Name:





City:





State:


All States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
District Of Columbia
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming





This is me
Searching for yourself?




Search





  This secure connection is confirmed




We're Very Popular















What Our Happy Users Are Saying




"TruthFinder.com is freakishly accurate… Really scary how much info is out there." -Zac K.


"You found an old friend for me. Thank you." -Nancy V.


"TruthFinder is an excellent site for finding out about someone." -Sherrie F.


"This site is so wonderful. I found my lost godchildren and their mom. Thank you so much." -Lawrence W.


"This is one way to really know a potential date." -Charmaine R.


"Your service is more than perfect. It is a blessing. Thank you for the very hard work that you do." -Richard B.


"Truthfinder is a very accurate updated system. Their information is proper. And can be very helpful too." -Juan M.









Notice
This site contains REAL police records (court records of driving citations, speeding tickets, felonies, misdemeanors, sexual offenses, mugshots, etc.), background reports, photos, court documents, address information, phone numbers, and much more. Please BE CAREFUL when conducting a search and ensure all the information you enter is accurate.
Learning the truth about the history of your family and friends can be shocking, so please be cautious when using this tool.
TruthFinder does not provide consumer reports and is not a consumer reporting agency. We provide a lot of sensitive information that can be used to satisfy your curiosity, protect your family, and find the truth about the people in your life. You may not use our service or the information it provides to make decisions about consumer credit, employers, insurance, tenant screening, or any other purposes that would require FCRA compliance.
I Understand


Help Us Refine Your Results
Select Your Gender



Male



Female

NEXT

Skip






















Background Checks and Public Records Search - Truthfinder








 


















Call Toll Free!  (800) 699-8081



 Public Records Search
Social Media, Photos, Police Records, Background Checks, Contact Information and Much More!









START HERE - Try searching a friend, relative, celebrity, yourself, or someone else you might know...



First Name:





Last Name:





City:





State:


All States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
District Of Columbia
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming





This is me
Searching for yourself?




Search





  This secure connection is confirmed




We're Very Popular















What Our Happy Users Are Saying




"TruthFinder.com is freakishly accurate… Really scary how much info is out there." -Zac K.


"You found an old friend for me. Thank you." -Nancy V.


"TruthFinder is an excellent site for finding out about someone." -Sherrie F.


"This site is so wonderful. I found my lost godchildren and their mom. Thank you so much." -Lawrence W.


"This is one way to really know a potential date." -Charmaine R.


"Your service is more than perfect. It is a blessing. Thank you for the very hard work that you do." -Richard B.


"Truthfinder is a very accurate updated system. Their information is proper. And can be very helpful too." -Juan M.









Notice
This site contains REAL police records (court records of driving citations, speeding tickets, felonies, misdemeanors, sexual offenses, mugshots, etc.), background reports, photos, court documents, address information, phone numbers, and much more. Please BE CAREFUL when conducting a search and ensure all the information you enter is accurate.
Learning the truth about the history of your family and friends can be shocking, so please be cautious when using this tool.
TruthFinder does not provide consumer reports and is not a consumer reporting agency. We provide a lot of sensitive information that can be used to satisfy your curiosity, protect your family, and find the truth about the people in your life. You may not use our service or the information it provides to make decisions about consumer credit, employers, insurance, tenant screening, or any other purposes that would require FCRA compliance.
I Understand


Help Us Refine Your Results
Select Your Gender



Male



Female

NEXT

Skip






















Background Checks and Public Records Search - Truthfinder








 


















Call Toll Free!  (800) 699-8081



Public Records Search
Social Media, Photos, Police Records, Background Checks, Contact Information and Much More!









START HERE - Try searching a friend, relative, celebrity, yourself, or someone else you might know...




First Name:





Last Name:





City:





State:


All States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
District Of Columbia
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming





check for social media accounts:




















This is me
Searching for yourself?




Search






  This secure connection is confirmed




We're Very Popular















What Our Happy Users Are Saying




"TruthFinder.com is freakishly accurate… Really scary how much info is out there." -Zac K.


"You found an old friend for me. Thank you." -Nancy V.


"TruthFinder is an excellent site for finding out about someone." -Sherrie F.


"This site is so wonderful. I found my lost godchildren and their mom. Thank you so much." -Lawrence W.


"This is one way to really know a potential date." -Charmaine R.


"Your service is more than perfect. It is a blessing. Thank you for the very hard work that you do." -Richard B.


"Truthfinder is a very accurate updated system. Their information is proper. And can be very helpful too." -Juan M.









Notice
This site contains REAL police records (court records of driving citations, speeding tickets, felonies, misdemeanors, sexual offenses, mugshots, etc.), background reports, photos, court documents, address information, phone numbers, and much more. Please BE CAREFUL when conducting a search and ensure all the information you enter is accurate.
Learning the truth about the history of your family and friends can be shocking, so please be cautious when using this tool.
TruthFinder does not provide consumer reports and is not a consumer reporting agency. We provide a lot of sensitive information that can be used to satisfy your curiosity, protect your family, and find the truth about the people in your life. You may not use our service or the information it provides to make decisions about consumer credit, employers, insurance, tenant screening, or any other purposes that would require FCRA compliance.
I Understand


Help Us Refine Your Results
Select Your Gender



Male



Female

NEXT

Skip






















Background Checks and Public Records Search - Truthfinder








 


















Call Toll Free!  (800) 699-8081



Public Records Search
Social Media, Photos, Police Records, Background Checks, Contact Information and Much More!









START HERE - Try searching a friend, relative, celebrity, yourself, or someone else you might know...



First Name:





Last Name:





City:





State:


All States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
District Of Columbia
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming





This is me
Searching for yourself?




Search





  This secure connection is confirmed




We're Very Popular















What Our Happy Users Are Saying




"TruthFinder.com is freakishly accurate… Really scary how much info is out there." -Zac K.


"You found an old friend for me. Thank you." -Nancy V.


"TruthFinder is an excellent site for finding out about someone." -Sherrie F.


"This site is so wonderful. I found my lost godchildren and their mom. Thank you so much." -Lawrence W.


"This is one way to really know a potential date." -Charmaine R.


"Your service is more than perfect. It is a blessing. Thank you for the very hard work that you do." -Richard B.


"Truthfinder is a very accurate updated system. Their information is proper. And can be very helpful too." -Juan M.









Notice
This site contains REAL police records (court records of driving citations, speeding tickets, felonies, misdemeanors, sexual offenses, mugshots, etc.), background reports, photos, court documents, address information, phone numbers, and much more. Please BE CAREFUL when conducting a search and ensure all the information you enter is accurate.
Learning the truth about the history of your family and friends can be shocking, so please be cautious when using this tool.
TruthFinder does not provide consumer reports and is not a consumer reporting agency. We provide a lot of sensitive information that can be used to satisfy your curiosity, protect your family, and find the truth about the people in your life. You may not use our service or the information it provides to make decisions about consumer credit, employers, insurance, tenant screening, or any other purposes that would require FCRA compliance.
I Understand


Help Us Refine Your Results
Select Your Gender



Male



Female

NEXT

Skip
















